Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpha Cognition Inc (OP: ACOGF )

0.3905 -0.0135 (-3.34%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,640
Open 0.4394
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.4040
Today's Range 0.3800 - 0.4394
52wk Range 0.2288 - 0.7398
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alpha Cognition Announces Change of Officer
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
From Alpha Cognition Inc.
Via Business Wire

Performance

YTD
-21.90%
-21.90%
1 Month
-10.27%
-10.27%
3 Month
-25.33%
-25.33%
6 Month
-29.85%
-29.85%
1 Year
+25.97%
+25.97%

More News

Read More
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
From Alpha Cognition Inc.
Via Business Wire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
From Virtual Investor Conferences
Via GlobeNewswire
Alpha Cognition to Present at the Life Science Investor Forum March 7th
From Virtual Investor Conferences
Via GlobeNewswire
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Provides Business Update
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Life Science Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
From Virtual Investor Conferences
Via GlobeNewswire
Alpha Cognition Launches $6.5 Million Private Placement
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Provides Private Placement Update
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.